D. Kowalski

R. Dziadziuszko, M. Krzakowski, D. Kowalski, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A long-term survival of 45-year old patient with primary metastatic prostate cancer - case report

M. Krzakowski, T. Jędrzejczak, D. Kowalski, 2005 .

Tracheal cancer in a 25-year-old woman — diagnostic difficulties

M. Krzakowski, D. Kowalski, A. Piórek, 2018, Oncology in Clinical Practice.

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy

P. Krawczyk, A. Płużański, D. Kowalski, 2022, Cancers.

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

J. Lunceford, M. Ayers, R. Herbst, 2019, Annals of Oncology.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

K. Nackaerts, J. Aerts, F. Grosso, 2017, The Lancet. Oncology.

Primary prophylaxis of febrile neutropenia with granulocyte stimulating factors in patient with locally advanced non-small cell lung cancer - case report

D. Kowalski, M. Knetki-Wróblewska, 2012 .

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

T. Mok, Yi-long Wu, B. Cho, 2018, Journal of Clinical Oncology.

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

J. Lunceford, M. Ayers, R. Herbst, 2019 .

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review

M. Krzakowski, D. Kowalski, K. Wojas-Krawczyk, 2022, Journal of clinical medicine.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Carlos Barrios, Toyoaki Hida, Keunchil Park, 2017, The Lancet.

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients

M. Szczyrek, P. Krawczyk, J. Milanowski, 2021, Frontiers in Oncology.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

L. Bubendorf, R. Stahel, S. Peters, 2018, Clinical Cancer Research.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First‐Line Therapy in Patients with Extensive‐Disease Small Cell Lung Cancer

R. Govindan, S. Novello, E. Juhász, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].

P. Krawczyk, W. Olszewski, R. Dziadziuszko, 2014, Pneumonologia i alergologia polska.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

L. Sequist, M. Ahn, J. Yang, 2020, The Lancet. Oncology.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC.

J. Lunceford, M. Ayers, T. Mok, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Preventing central nervous system metastases in non-small cell lung cancer

P. Krawczyk, D. Kowalski, R. Duchnowska, 2018, Expert review of anticancer therapy.

Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

A. Tafreshi, Ying Cheng, B. Halmos, 2018, The New England journal of medicine.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

T. Mok, I. Bondarenko, B. Karaszewska, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statement on a screening programme for the detection of early lung cancer in Poland.

T. Zdrojewski, R. Dziedzic, E. Jassem, 2018, Advances in respiratory medicine.

Two neoplasms rich in small lymphocytes, B1B2 thymoma and small lymphocytic lymphoma, intermingled in one tumor mass. A case report.

J. Zaremba, D. Kowalski, M. Prochorec-Sobieszek, 2017, Polish journal of pathology : official journal of the Polish Society of Pathologists.

Prognostic significance of sex in patients with primary tracheal tumors – a retrospective, single-center study

M. Krzakowski, A. Płużański, D. Kowalski, 2022, Nowotwory. Journal of Oncology.

Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer

P. Krawczyk, J. Milanowski, B. Kuźnar-Kamińska, 2016, Tumor Biology.

Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.

P. Krawczyk, J. Milanowski, D. Kowalski, 2015, Translational research : the journal of laboratory and clinical medicine.

Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome

M. Krzakowski, A. Płużański, D. Kowalski, 2019, Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery.

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

A. Mansfield, A. Tsao, P. Baas, 2020 .

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer

P. Krawczyk, D. Kowalski, 2013, Contemporary oncology.

Intensity-modulated radiation therapy as adjuvant treatment for local advanced malignant mesothelioma after pleuropneumonectomy – report of two cases

M. Krzakowski, Dariusz Garmol, T. Orlowski, 2011 .

[Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma].

W. Olszewski, R. Dziadziuszko, R. Ramlau, 2010, Pneumonologia i alergologia polska.

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer

M. Krzakowski, S. Szmit, D. Kowalski, 2020, Journal of clinical medicine.

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.

N. Reinmuth, D. Planchard, R. Soo, 2020, Annals of Oncology.

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer

P. Krawczyk, J. Milanowski, D. Kowalski, 2012, Contemporary oncology.

[Systemic treatment of non-small cell lung cancer--recommendations based on the results of reliable clinical trials].

W. Olszewski, R. Dziadziuszko, R. Ramlau, 2007, Pneumonologia i alergologia polska.

Recommendations on the systemic treatment of non-small cell lung cancer:a Round Table Conference

W. Olszewski, R. Dziadziuszko, R. Ramlau, 2005 .

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

P. Ascierto, R. Plummer, E. Felip, 2022, Cancer Chemotherapy and Pharmacology.

Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)

J. Bosch-Barrera, L. Ciuffreda, G. de Castro, 2021, Therapeutic advances in medical oncology.

Thymic epithelial tumors: Do we know all the prognostic factors?

M. Krzakowski, D. Kowalski, M. Szołkowska, 2021, Thoracic cancer.

[Gefitinib in patients with advanced non-small-cell lung cancer].

M. Krzakowski, A. Płużański, D. Kowalski, 2012, Pneumonologia i alergologia polska.

Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment

M. Krzakowski, D. Kowalski, A. Janowicz-Żebrowska, 2011 .

EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence.

W. Olszewski, M. Krzakowski, J. Siedlecki, 2013, International journal of clinical and experimental pathology.

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study

P. Krawczyk, J. Milanowski, R. Dziadziuszko, 2014, Journal of Cancer Research and Clinical Oncology.

The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

P. Krawczyk, J. Milanowski, M. Krzakowski, 2012, Chemotherapy.

Elderly patients treatment with non-small-cell lung cancer

M. Krzakowski, D. Kowalski, 2012 .

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

P. Krawczyk, J. Milanowski, M. Krzakowski, 2011, Respiration.

Adenoid cystic carcinoma of the lung — a case report

M. Krzakowski, A. Płużański, D. Kowalski, 2019 .

A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role

M. Krzakowski, A. Płużański, D. Kowalski, 2021, Journal of contemporary brachytherapy.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Keunchil Park, N. Reguart, S. Jabbour, 2021, JAMA oncology.

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.

N. Reguart, S. Jabbour, M. Reck, 2022, Journal of Clinical Oncology.

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice

M. Krzakowski, A. Płużański, D. Kowalski, 2022, Current oncology.

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy

M. Krzakowski, S. Szmit, A. Płużański, 2023, Cancers.

PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)

R. Ramlau, S. Ramalingam, D. Fennell, 2017 .

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials

M. Krzakowski, D. Kowalski, M. Knetki-Wróblewska, 2020, Journal of clinical medicine.

Lung Cancer in Poland.

P. Krawczyk, W. Olszewski, R. Dziadziuszko, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients

P. Krawczyk, J. Milanowski, R. Ramlau, 2015, Pathology & Oncology Research.

Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.

P. Krawczyk, J. Milanowski, R. Ramlau, 2014, Clinical lung cancer.

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients

P. Krawczyk, J. Milanowski, R. Ramlau, 2014, Journal of Cancer Research and Clinical Oncology.

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

A. Tafreshi, Ying Cheng, L. Paz-Ares, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles.

L. Schwartzberg, M. Karthaus, D. Kowalski, 2017 .

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

R. Gralla, E. Roeland, R. Navari, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

F. de Marinis, G. Ceresoli, R. Ramlau, 2021, ESMO open.

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Jie Yang, L. Sequist, M. Ahn, 2022, Cancer discovery.

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients

R. Dziadziuszko, M. Krzakowski, A. Płużański, 2020, ESMO Open.

Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.

J. Milanowski, R. Dziadziuszko, R. Ramlau, 2020, Advances in respiratory medicine.

Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study.

A. Shaw, C. Chiu, B. Solomon, 2021 .

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

G. Bepler, R. Ramlau, D. Talbot, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice

M. Krzakowski, A. Płużański, D. Kowalski, 2023, Journal of clinical medicine.

FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC

T. Mok, B. Karaszewska, K. Kubota, 2021 .

FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

P. Jänne, L. Sequist, J.-Y. Han, 2021 .

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

Keunchil Park, N. Reguart, S. Jabbour, 2021 .

Abstract CT084: Relationship betweenSTK11andKEAP1mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC

J. Lunceford, M. Ayers, T. Mok, 2020, Tumor Biology.

Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer

P. Krawczyk, J. Milanowski, D. Kowalski, 2017, International Journal of Colorectal Disease.

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer

M. Krzakowski, S. Szmit, D. Kowalski, 2023, Current oncology.

MA10.08 Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Ying Cheng, B. Halmos, L. Paz-Ares, 2018, Journal of Thoracic Oncology.

DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)

M. Reck, V. Gorbounova, F. Grossi, 2012 .

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

M. A. Ayers, R. Herbst, Yi-long Wu, 2021, Journal for ImmunoTherapy of Cancer.

Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

F. Ciardiello, F. Barlesi, M. Ballinger, 2017, Pneumologie.

Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).

L. Bubendorf, R. Stahel, S. Peters, 2017 .

Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer.

A. Shaw, C. Chiu, P. Tomasini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Keunchil Park, Yi-long Wu, F. de Marinis, 2021, Frontiers in Oncology.

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).

R. Ramlau, S. Ramalingam, D. Fennell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

A. Mansfield, S. Peters, A. Tsao, 2022, Lung cancer.

First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

S. Peters, A. Tsao, P. Baas, 2021, Pneumologie.

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

A. Tafreshi, Ying Cheng, B. Halmos, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

F. Cappuzzo, A. Szczesna, H. K. Vollan, 2023, The Lancet.

Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials

Cheng-Ta Yang, Y. Wu, C. Zhou, 2019, Annals of Oncology.

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI

L. Sequist, M. Ahn, W. Su, 2019, Annals of Oncology.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2023, The New England journal of medicine.

Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.

N. Reinmuth, P. Paik, E. Felip, 2020 .

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

L. Sequist, M. Ahn, J. Yang, 2019, SSRN Electronic Journal.

Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.

C. Gridelli, M. Krzakowski, M. Di Maio, 2012, Lung cancer.

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland

R. Ramlau, M. Krzakowski, D. Kowalski, 2012, Contemporary oncology.

A. Tafreshi, S. Novello, R. Ramlau, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of Clinical Oncology.

Michael Thomas, E. Smit, P. Paik, 2020 .

IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen

F. Cappuzzo, A. Szczesna, Geoffrey Liu, 2022, Social Science Research Network.

Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.

B. Mellado, M. Monga, E. Felip, 2020 .

Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment

D. Kowalski, A. Janowicz-Żebrowska, Maciej Krzakowski, 2011 .

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

P. Krawczyk, J. Milanowski, M. Krzakowski, 2011, Respiration.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

K. Nackaerts, J. Aerts, F. Grosso, 2017, The Lancet. Oncology.

Intensity-modulated radiation therapy as adjuvant treatment for local advanced malignant mesothelioma after pleuropneumonectomy – report of two cases

M. Krzakowski, Dariusz Garmol, T. Orlowski, 2011 .

ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment.

N. Reinmuth, D. Planchard, R. Soo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.

C. Gridelli, M. Krzakowski, M. Di Maio, 2012, Lung cancer.

Prognostic score for second-line chemotherapy of advanced non-small cell lung cancer (NSCLC): External validation in a phase III trial comparing vinflunine with docetaxel.

C. Gridelli, M. Krzakowski, M. Di Maio, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Jie Yang, N. Reinmuth, E. Smit, 2020, The New England journal of medicine.

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.

N. Reguart, S. Jabbour, M. Reck, 2020 .

363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer

Yi-long Wu, T. Mok, B. Karaszewska, 2021, Journal for ImmunoTherapy of Cancer.

Consensus statement on a screening programme for the detection of early lung cancer in Poland.

T. Zdrojewski, R. Dziedzic, E. Jassem, 2018, Advances in respiratory medicine.

Predictive factors testing proposal for NSCLC patients during the COVID-19 pandemic

P. Krawczyk, R. Dziadziuszko, D. Kowalski, 2021, Expert review of anticancer therapy.

Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867.

G. Giaccone, M. Ahn, H. Borghaei, 2022, Journal of Clinical Oncology.

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice

P. Krawczyk, D. Kowalski, E. Kalinka, 2024, Frontiers in oncology.